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Introduction: Multiple biologically relevant polymorphisms may
have more accurate prediction of cancer prognosis compared with
single polymorphism because of the modest effect. This study investi-
gated whether the functional polymorphisms in P53 pathway genes,
P53 Arg72Pro (rs1042522), P73 G4C14-to-A4T14 (rs2273953 and
rs1801173), and MDM2 T309G (rs2279744), alone or in combina-
tion, affect survival in advanced non-small cell lung cancer
(NSCLC) patients.
Methods: A total of 199 stage III–IV NSCLC patients with plati-
num-based chemotherapy were recruited between 2002 and 2004.
Associations between genotypes and survival were assessed using
Kaplan-Meier method. Cox proportional hazard models were per-
formed to identify significant variables.
Results: During the median 26.5 months of follow-up, the P53
Pro/Pro genotype was strongly associated with shorter overall sur-
vival compared with the Arg/Arg genotype (12.0 versus 20.0
months; log-rank p  0.002; hazard ratio  1.86; 95% confidence
interval [CI], 1.15–3.02). Pairwise combination analysis showed that
patients carrying the variant P53 Pro/Pro-P73 GC/GC or P53
Pro/Pro-MDM2 GG genotypes had survival time only half of that for
those carrying the wild-type genotypes, with hazard ratio being 2.47
(95% CI, 1.20–5.10) and 2.00 (95% CI, 1.15–3.46), respectively.
Furthermore, a combined effect was seen with survival time being
gradually shorter with increasing number of unfavorable genotypes
in these three genes (ptrend  0.039), indicating a gene-dose effect in
association with survival.
Conclusions: These findings suggest that genetic polymorphisms in
the P53 pathway may be promising biomarkers for individualized
chemotherapy and prognosis of NSCLC patients.
Key Words: Non-small cell lung cancer, Survival, P53, P73,
MDM2.
(J Thorac Oncol. 2011;6: 1793–1800)
For the disseminated non-small cell lung cancer (NSCLC)patients, systemic chemotherapy is the only proven ap-
proach of treatment, of which platinum agent as one of the
most active anticancer agents has been widely used and
yielded improved patient survival.1 However, great interindi-
vidual variability in response to platinum drugs correlated to
a spectrum of outcomes ranging from limited therapeutic
effect to toxic reaction occurred among patients.2 Recently,
pharmacogenetic studies evolving from single genetic poly-
morphism to microarray-based interrogation of thousand
genes have tried to identify biomarkers that may predict
individual outcome of chemotherapy aiming to select patients
who would derive significant benefit from maximized effi-
cacy and minimal toxicity. However, few or none has been
established in the clinical setting yet.3
Platinum drugs kill tumor cells by means of cytotoxic
mechanism, which is mostly used by the formation of plati-
num-DNA adducts and ultimately triggering apoptosis.4
Emerging evidence has suggested that functional single-
nucleotide polymorphisms (SNPs) involved in cell-cycle con-
trol, DNA repair, and apoptosis may modulate response to
platinum-based chemotherapy and affect outcome of NSCLC
patients treated with the regimen.2,3
P53, a well-recognized transcriptional factor, regulates
the expression, cellular location, and activity of key compo-
nents in cellular processes including cell-cycle arrest, DNA
repair, and apoptotic cell death in response to cellular stress
including chemotherapy.5 Therefore, normal P53 activity is
critical for chemosensitivity of cancer cells, and chemoresis-
tance may be developed when P53 activity is inhibited.4
Multiple functional SNPs occur in the P53 gene and the most
frequently studied is the G to C change at codon 72 in exon
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4 resulting in the amino acid substitution of Arg to Pro
(Arg72Pro, rs1042522). This SNP has been shown to alter
P53 function because it is located in the proline-rich region
that is required for P53 to induce apoptosis.6 Emerging
evidence has shown that the P53 Arg72Pro polymorphism is
not only associated with lung cancer risk but also affects
individual sensitivity to platinum-drug chemotherapy and
patients’ survival.7–11
In response to cellular stress, the activation of P53 also
requires communication and coordination with other compo-
nents of the P53 pathway where P53 acts as a central node
and a set of genes are involved in cell-cycle arrest and
apoptosis. In the P53 pathway, P73 is a structural and func-
tional homologue of P53 that can bind to the P53 responsive
elements and transactivate an overlapping set of P53 target
genes and thus also implicated in cell-cycle control and
apoptotic cell death.7 Accumulating evidence has demon-
strated that P73 is essential for apoptosis induced by platinum
drugs, and inactivation of P73 by mutations leads to resis-
tance of tumor cells to cytotoxic agents.8,9 Although P73
mutation is rare in all cancers, loss of heterozygosity at P73
locus is relatively common in cancer including lung cancer.10
Two common SNPs at nucleotides 4 (G to A) and 14 (C to T)
in the 5 untranslated region of exon 2 in P73 (G4C14-to-
A4T14; rs2273953, rs1801173) have been identified to be in
complete linkage disequilibrium with each other as one vari-
ation. This dinucleotide polymorphism lies just upstream of
the initiating AUG of exon 2, a region of the transcript that
may theoretically form a stem-loop structure and possibly
affect the gene expression.11 The association of this dinucle-
otide polymorphism with risk of NSCLC has been docu-
mented in several epidemiological studies.12–14 However, the
role of the P73 G4C14-to-A4T14 polymorphism in response
to platinum-drug chemotherapy and prognosis of NSCLC has
not been investigated. Another major regulator of P53 is
human homolog of mouse double minute 2 (MDM2), which
inhibits P53 activity by directly binding to the N-terminal
transcription of domain, mediating P53 location and degra-
dation through the ubiquitination system.15 Under physio-
logic conditions, P53 is maintained at low level by MDM2
for normal cell growth. However, overexpression of MDM2
may attenuate P53 function, enabling damaged cells to escape
the cell cycle checkpoint control.16 Numerous studies have
shown that a subset of tumors overexpressed MDM2, which
was associated with cancer progression and lack of response
to chemotherapy.17–19 A common T to G polymorphism at
nucleotide 309 (T309G, rs2279744) in the promoter region of
MDM2 has been widely investigated in cancer, and the results
suggested that this polymorphism may accelerate cancer
progression and prevent tumor cells from killing by chemo-
therapy because of its association with increased MDM2
expression and attenuated activity of P53 pathway.20–22
Because of the key role of the P53 pathway in cellular
process in response to DNA damage, we hypothesized that
the functional polymorphisms in P53, P73, and MDM2 may
have cooperatively impact on outcome of NSCLC treated
with platinum-based chemotherapy. To test this hypothesis,
we recruited 199 advanced NSCLC patients treated with
platinum-based chemotherapy and investigated whether the
functional polymorphisms in these genes, alone or in combi-
nation, affect patients’ survival.
PATIENTS AND METHODS
Patients
Patients with histologically confirmed NSCLC who
received platinum-based chemotherapy were enrolled be-
tween September 2002 and October 2004 from Cancer Hos-
pital of Chinese Academy of Medical Sciences (Beijing,
China). The eligible patients were required to have patholog-
ically documented stage III or IV NSCLC, measurable le-
sions, Eastern Cooperative Oncology Group (ECOG) perfor-
mance status of 0, 1, or 2, and normal results of completed
blood counts, liver function, and urinalysis. Pretreatment
staging involved medical history and physical examination,
chest x-ray, chest computed tomography scan, bone scan, and
abdominal ultrasonogram. A total of 199 patients were eligi-
ble to participate in this study and had adequate blood DNA
for genotyping. All the patients had completed follow-up and
clinical information. Demographic and clinical data were
systemically recorded at entry (including age, gender, smok-
ing status, performance status, disease stage, and tumor
histology) and along follow-up (treatment regimen, tumor
recurrence and/or metastasis, and death). In this study, smok-
ing status was categorized as never-smoker (having smoked
less than 100 cigarettes during their lifetime) or ever-smoker
(current smoker and ex-smoker). Written informed consent
for the use of DNA sample and clinical information was
obtained from each subject. The study was conducted under
the approval of the institutional review boards of the Chinese
Academy of Medical Sciences Cancer Institute and the
Tongji Medical College of Huazhong University of Science
and Technology.
SNP Genotyping
Genomic DNA was extracted from blood sample col-
lected from each patient at the time of recruitment. P53
Arg72Pro genotypes were determined by polymerase chain
reaction-restriction fragment length polymorphism assay,23
whereas P73 G4C14-to-A4T14 and MDM2 T309G genotypes
were determined using the tetra-amplification refractory mu-
tation system-polymerase chain reaction method.23,24 A 15%
blind, random sample of study subjects was genotyped twice,
and the reproducibility was 100%.
Statistical Analysis
Association between genotypes and demographic or
clinical characteristics of patients were assessed using 2 test.
For each polymorphism, the Hardy-Weinberg equilibrium
was tested by Person’s 2 test. Overall survival (OS) was
calculated as the time from diagnosis to lung cancer-related
death or the date of last follow-up. Progression-free survival
(PFS) was taken from the date of diagnosis to the date of
disease progression, death without progression, or last fol-
low-up. Median follow-up time was calculated among cen-
sored observations only. Association between genotypes and
survival were estimated using the Kaplan-Meier method, and
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statistical significance was assessed by the log-rank test. Cox
proportional hazards models were used to evaluate the inde-
pendent effect of genetic polymorphisms on OS and PFS
adjusted for age, gender, performance status, smoking status,
tumor stages, histological type, and chemotherapy. The joint
effect of P53, P73, and MDM2 genotypes on NSCLC sur-
vival was also evaluated. All tests were two-tailed with p less
than 0.05 as significant level. All statistical analyses were
performed using software SPSS v12.0.
RESULTS
Patient Characteristics and Clinical Outcomes
The main demographic and clinical characteristics of
patients are shown in Table 1. By the time of the final
analysis (May 31, 2008), the median follow-up time was 26.5
months (ranging from 6.0 to 60.0 months), and 159 patients
died of cancer. The median OS and PFS time were 16.0 (95%
confidence interval [CI], 13.5–18.5) and 6.9 (95% CI, 6.0–
7.8) months, respectively. Overall, age, sex, smoking, ECOG
performance, histological type, disease stages, and chemo-
therapy regimens were not significantly associated with pa-
tients’ OS and PFS in this study.
Association Between Single Genotype and
Patients’ OS or PFS
The frequency distributions of all genotypes among
patients are presented in Table 2. All genotype frequencies
for the P53 Arg72Pro, P73 G4C14-to-A4T14, and MDM2
T309G were in Hardy-Weinberg equilibrium (p  0.860,
0.233, and 0.803, respectively). No associations were de-
tected between any of these polymorphisms and sex, age,
performance status, smoking status, histological type, disease
stages, or chemotherapy regimens.
The P53 Arg72Pro polymorphism was significantly
associated with patients’ survival. Patients with the Pro/Pro
genotype had median OS of 12.0 (95% CI, 8.5–15.5) months
significantly shorter than that for those with the Arg/Arg
genotype (median OS, 20.0 months; 95% CI, 15.3–24.7
months; log-rank p  0.002; Figure 1). Moreover, patients
TABLE 1. Patient, Treatment, and Follow-Up Characteristics
Characteristics n (%)
Median age, yr (range) 56 (29–74)
Sex
Female 70 (35.2)
Male 129 (64.8)
Smoking status
Smoker 118 (59.3)
Never-smoker 81 (40.7)
ECOG performance status
0 99 (49.7)
1 73 (36.7)
2 27 (13.6)
Histology
Adenocarcinoma 139 (69.8)
Squamous carcinoma 36 (18.1)
Adenosquamous 24 (12.1)
Disease stage
III (A/B) 43 (21.6)
IV 156 (78.4)
Chemotherapy regimens
Cisplatin  vinorelbine/taxane 141 (70.9)
Carboplatin  vinorelbine/taxane 45 (22.6)
Oxaliplatin  vinorelbine 13 (6.5)
Median follow-up time (mo) 26.5
Events, deaths 159 (79.9)
Median survival time (mo) 16.0
ECOG, Eastern Cooperative Oncology Group.
TABLE 2. Associations Between P53 Arg72Pro, P73 G4C14-to-A4T14, and MDM2 T309G Genotypes and NSCLC Survival
Genotype n
Overall Survival Progression-Free Survival
Median (mo) Log-Rank p HRa 95% CI Median (mo) Log-Rank p HRa 95% CI
P53 Arg72Pro
Arg/Arg 58 20.0 Referent 7.6 Referent
Arg/Pro 100 16.0 0.095 1.46 1.00–2.15 6.9 0.085 1.45 0.98–2.15
Pro/Pro 41 12.0 0.002 1.86 1.15–3.02 5.3 0.004 1.99 1.23–3.22
ptrend 0.009 0.005
P73 G4C14-to-A4T14
GC/GC 114 16.0 Referent 6.5
GC/AT 69 17.0 0.732 0.97 0.69–1.39 8.3 0.119 0.79 0.56–1.13
AT/AT 16 18.0 0.709 0.83 0.44–1.57 5.7 0.769 1.15 0.61–2.19
ptrend 0.606 0.574
MDM2 T309G
TT 44 17.0 Referent 6.6 Referent
TG 101 17.0 0.615 0.88 0.58–1.34 6.5 0.985 1.05 0.69–1.60
GG 54 15.0 0.914 1.05 0.66–1.67 9.0 0.140 0.70 0.44–1.12
ptrend 0.769 0.099
a Adjusted for sex, age, smoking status, performance status, stages, histology, and chemotherapy regimens.
NSCLC, non-small cell lung cancer; HR, hazard ratio; CI, confidence interval.
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with the heterozygous Arg/Pro genotype also had shorter OS
(median OS, 16.0 months; 95% CI, 12.8–19.2 months) com-
pared with carriers of the Arg/Arg genotype, although the
difference was marginally significant (log-rank p  0.095).
Combined analysis showed that patients carrying at least one
P53 72Pro allele had significant shorter OS (median OS, 14.0
months; 95% CI, 11.0–17.0 months) than patients carrying
no such an allele (log-rank p  0.021). Similarly, significant
association was also observed between P53 Arg72Pro
polymorphism and PFS (Table 2; Figure 1). The median
PFS for the Arg/Arg genotype was 7.6 (95% CI, 5.7–9.5)
months, which was significantly longer than that for the
Pro/Pro genotype (median PFS, 5.3 months; 95% CI,
4.1– 6.5 months; log-rank p  0.004) or that for combined
variant genotypes (median PFS, 6.5 months; 95% CI,
5.8 –7.2 months; log-rank p  0.020). In Cox proportional
hazards model including age, sex, ECOG performance
status, smoking status, histological type, disease stage, and
chemotherapy regimens as covariates, the prognostic sig-
nificance of P53 Arg72Pro polymorphism for OS still
existed. Compared with the Arg/Arg genotype, the Arg/Pro
and Pro/Pro genotypes had significantly higher risk of
death, with HRs being 1.46 (95% CI, 1.00–2.15) and 1.86
(95% CI, 1.15–3.02), respectively (ptrend  0.009). Similarly,
multivariate Cox proportional hazards model also demon-
strated an allele-dose effect for the P53 Arg72Pro polymor-
phism on PFS (ptrend  0.005), with the Pro/Pro genotype
having the highest hazard ratio (HR) of 1.99 (95% CI, 1.23–
3.22). Nevertheless, no significant associations were observed
between patients’ survival and the P73 G4C14-to-A4T14 or
MDM2 T309G genotypes (Table 2).
Association Between Combined Genotypes
and Patients’ OS and PFS
In combined analysis of P53 Arg72Pro and P73
G4C14-to-A4T14 polymorphisms (Table 3), patients with the
P53 Pro/Pro-P73 GC/AT  AT/AT or P53 Pro/Pro-P73
GC/GC genotypes had significantly shorter OS compared
with those carrying the P53 Arg/Arg-P73 GC/AT  AT/AT
genotypes (12.0 versus 24.0 months; log-rank p  0.031 and
10.0 versus 24.0 months; log-rank p  0.001). Similarly,
shorter PFS was also presented in patients carrying both P53
72Pro and P73 4G14C alleles (Table 3; Figure 2). Moreover,
an allele-dose effect of combined P53 and P73 genotypes on
OS was found (Ptrend  0.009), with the P53 Pro/Pro-P73
GC/GC genotype having the highest HR of death (2.47; 95%
CI, 1.20–5.10). Similar results were seen for PFS, showing
that the combined genotypes P53 Arg/Pro-P73 GC/GC, P53
Pro/Pro-P73 GC/AT  AT/AT, or P53 Pro/Pro-P73 GC/GC
had poor PFS and increased HR compared with the P53
Arg/Arg-P73 GC/AT  AT/AT genotype (ptrend  0.003).
When the P53 Arg72Pro and MDM2 T309G polymor-
phisms were combined for analysis, shorter OS and PFS were
seen in patients with the P53 Pro/Pro-MDM2 GG genotype
than in patients with the P53 Arg/Arg-MDM2 TT  TG
genotype (median OS, 10 versus 20 months; log-rank p 
0.003 and median PFS, 5.5 versus 7.0 months, log-rank p 
0.037; Figure 3). Multivariate Cox proportional hazard model
showed an allele-dose effect of the combined P53 Pro and
MDM2 G variants on increase in HR for poor OS and PFS
(ptrend  0.006 and 0.024). Patients carrying two variant
alleles of both P53 72Pro and MDM2 309G (P53 Pro/Pro-
MDM2 GG genotypes) had HRs of 1.74 (95% CI, 1.01–3.01)
FIGURE 1. Kaplan-Meier curves of (A) overall survival (log-rank p  0.009) and (B) progression-free survival (log-rank p 
0.009) for all 199 non-small cell lung cancer patients with different P53 Arg72Pro genotypes.
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for cancer progression and 2.00 (95% CI, 1.15–3.46) for
death. The analysis for combined P73 G4C14-to-A4T14 and
MDM2 T309G genotypes was also performed, but no signif-
icant association was found (Table 3).
Finally, we evaluated the combined effect of the three
polymorphisms in P53, P73, and MDM2 genes, with the
genotypes associated with increased HR of death as unfavor-
able genotypes including the P53 Pro/Pro, Arg/Pro, P73
TABLE 3. Association Between Combined P53-P73 or P53-MDM2 Genotypes and NSCLC Survival
Genotypes n
Overall Survival Progression-Free Survival
Median (mo) Log-Rank p HRa 95% CI Median (mo) Log-Rank p HRa 95% CI
P53 P73
Arg/Arg GC/AT  AT/AT 24 24.0 Referent 11.2 Referent
Arg/Arg GC/GC 34 17.0 0.633 1.19 0.61–2.30 6.8 0.226 1.77 0.92–3.42
Arg/Pro GC/AT  AT/AT 39 17.0 0.141 1.70 0.93–3.13 7.1 0.089 2.01 1.09–3.70
Arg/Pro GC/GC 61 16.0 0.192 1.54 0.88–2.70 6.9 0.030 1.87 1.07–3.29
Pro/Pro GC/AT  AT/AT 22 12.0 0.031 1.79 0.91–3.51 6.1 0.011 2.35 1.18–4.65
Pro/Pro GC/GC 19 10.0 0.001 2.47 1.20–5.10 4.0 0.002 3.20 1.53–6.73
ptrend 0.009 0.003
P53 MDM2
Arg/Arg TT  TG 44 20.0 Referent 7.0 Referent
Arg/Arg GG 14 17.0 0.671 0.98 0.46–2.05 10.0 0.290 0.57 0.27–1.23
Arg/Pro TT  TG 76 16.0 0.184 1.37 0.88–2.14 6.5 0.232 1.35 0.85–2.15
Arg/Pro GG 24 15.0 0.082 1.72 0.97–3.04 8.3 0.816 1.00 0.57–1.77
Pro/Pro TT  TG 9 13.0 0.287 1.47 0.63–3.42 4.0 0.157 1.63 0.70–3.81
Pro/Pro GG 32 10.0 0.003 2.00 1.15–3.46 5.5 0.037 1.74 1.01–3.01
ptrend 0.006 0.024
MDM2 P73
TT  TG GC/AT  AT/AT 56 18.0 Referent 6.5 Referent
GG GC/AT  AT/AT 29 17.0 0.297 1.18 0.71–1.95 9.0 0.441 0.72 0.43–1.21
TT  TG GC/GC 89 16.0 0.583 1.09 0.73–1.64 6.5 0.258 1.17 0.77–1.77
GG GC/GC 25 9.0 0.280 1.26 0.72–2.22 7.0 0.723 0.77 0.43–1.35
ptrend 0.495 0.967
a Adjusted for sex, age, smoking status, performance status, stages, histology, and chemotherapy regimens.
NSCLC, non-small cell lung cancer; HR, hazard ratio; CI, confidence interval.
FIGURE 2. Kaplan-Meier curves of (A) overall survival (log-rank p  0.028) and (B) progression-free survival (log-rank p 
0.031) by combined P53 Arg72Pro and P73 G4C14-to-A4T14 genotypes.
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GC/GC, and MDM2 GG. On the basis of the number of
unfavorable genotypes carried, patients were categorized into
four groups: group 1, having no unfavorable genotype; group
2, having unfavorable genotypes in any one gene; group 3,
having unfavorable genotypes in any two genes; and group 4
having unfavorable genotypes in all three genes. We found
that the median OS is gradually shorter with increasing number
of unfavorable genotypes, and the HR for death also increased in
an allele-dose-dependent manner (ptrend  0.039), although the
association between the combined genotypes and OS was not
statistically significant (Table 4; Figure 4).
DISCCUSION
In this study, we evaluated the prognostic effect of
three functional polymorphisms in the P53 pathway in ad-
vanced NSCLC patients treated with platinum-based chemo-
therapy. We found that the P53 Arg72Pro polymorphism
played substantial role in the prognosis of NSCLC not only in
itself but also in combination with P73 G4C14-to-A4T14 and
MDM2 T309G polymorphisms. To the best of our knowl-
edge, this is the first study investigating the joint effect of
P53, P73, and MDM2 polymorphisms on prognosis of ad-
vanced NSCLC patients with platinum-based chemotherapy.
Accumulating evidence indicates that inherited varia-
tions in P53 pathway components may define patient popu-
lations in their abilities to produce apoptosis of cancer cells in
response to DNA damage induced by chemotherapeutic
agents.16,25 As one of the most frequently studied variations
in the P53 pathway, P53 Arg72Pro polymorphism has been
shown to affect prognosis of various cancers,26–30 although
the reported results are not all consistent for NSCLC pa-
tients.31–33 In this study, we found that patients carrying the
FIGURE 3. Kaplan-Meier curves of (A) overall survival (log-rank p  0.045) and (B) progression-free survival (log-rank p 
0.046) by combined P53 Arg72Pro and MDM2 T309G genotypes.
TABLE 4. Combined Effect of Polymorphisms in P53, P73, and MDM2 on NSCLC Survival
No. of Unfavorable
Genotypesa n
Overall Survival Progression-Free Survival
Median (mo) Log-Rank p HRb 95% CI Median (mo) Log-Rank p HRb 95% CI
0 (Group 1) 17 20.0 Referent 7.7 Referent
1 (Group 2) 73 18.0 0.576 1.16 0.60–2.24 6.8 0.440 1.35 0.70–2.30
2 (Group 3) 91 14.0 0.115 1.62 0.86–3.04 6.6 0.113 1.66 0.88–3.14
3 (Group 4) 18 10.0 0.243 1.60 0.72–3.60 7.0 0.750 1.10 0.50–2.34
ptrend 0.039 0.437
a The P53 Arg/Pro, Pro/Pro, P73 GC/GC, and MDM2 GG genotypes were considered as unfavorable genotypes. Group 1 carried no unfavorable genotypes in any gene, group
2 carried one unfavorable genotype in any one gene, group 3 carried unfavorable genotypes in any two genes, and group 4 carried unfavorable genotypes in all three genes.
b Adjusted for sex, age, smoking status, performance status, stages, histology, and chemotherapy regimens.
HR, hazard ratio; CI, confidence interval.
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P53 72Pro allele had both significantly poor OS and PFS.
This result is parallel to the laboratory findings showing that
apoptotic rate was higher in cells expressing the 72Arg
protein than in cells expressing the 72Pro protein in response
to platinum treatment.34 Furthermore, our result is consistent
with the recent study on NSCLC, reporting that patients with
the P53 72Pro/Pro genotype are more likely to be resistant to
platinum-based chemotherapy and display worse survival
than patients with the P53 72Arg/Arg genotype.31 Interest-
ingly, the variant 4A14T allele of G4C14-to-A4T14 polymor-
phism in the P73 gene showed a tendency of association with
longer survival in this study. This result is consistent with two
previous studies showing prognosis significance of the
4A14T allele for better survival in colorectal cancer and
breast cancer.35,36 Although to be elucidated, the underlying
mechanism for the association between the P73 G4C14-to-
A4T14 polymorphism and prognosis of cancer could be the
involvement of this polymorphism in P73 translational initi-
ating or alternative splicing.35,37 For the MDM2 T309G poly-
morphism, we did not observe its association with survival in
advanced NSCLC patients, which is consistent with the
observation from the study by Chien et al.38 that the T309G
polymorphism was not associated with survival in late-stage
patients, whereas inconsistent with previous studies reporting
significant association of this polymorphism with survival in
stage I NSCLC patients.38,39 This discrepancy might be due to
distinct disease stage between our study and previous studies.
In our study, the modest effect of genetic polymorphism
could be overwhelmed by complex somatic mutations that
occur in advanced cancer. Nevertheless, the reasons for the
inconsistent results between previous studies and ours need to
be explored in further studies.
Intriguingly, analysis of the collective effect of P53
Arg72Pro, P73 G4C14-to-A4T14, and MDM2 T309G poly-
morphisms showed an association of combined genotypes
with survival in a genotype-dose effect manner. These results
are in line with the functional interactions among these three
polymorphisms in P53, P73, and MDM2. Previous studies
have shown a cooperation effect between P53 and P73 in
platinum-induced apoptosis in vitro in cancer cell lines.37,40
In addition, previous study also showed that the influence of
P53 72Arg72Pro polymorphism on response to platinum-
based cancer chemotherapy in head and neck cancer patients
is through modulation of P73-dependent apoptosis, suggest-
ing a P53-P73 interaction.8 Because MDM2 and P53 are in a
feedback loop,41 joint effect between P53 Arg72Pro and
MDM2 T309G polymorphisms are biologically plausible. It
has been shown that the P53 72Pro variant displays more
compacted affinity for the TAFII32 and TAFII70 transcrip-
tional factors compared with the 72Arg variant and thus had
higher ability to transactivate MDM2 309G allele.42 More-
over, P73 and MDM2, the two regulators of P53 function,
also interact with each other in the P53 pathway. MDM2 can
bind to the N-terminal domain of P73 because of the struc-
tural similarity of P73 and P53 but not degrade P73,43
whereas P73 can elevate the level of MDM2 by increasing
transcription and protein stability of MDM2.44 Thus, the
activity of P53 could be altered by cooperation between
MDM2 and P73. In view of the interactions among P53, P73,
and MDM in apoptosis, one may expect that the functional
polymorphisms in the P53, P73, and MDM2 genes have joint
effect on response to and outcome of chemotherapy.
In conclusion, our results showed a substantial cumulative
effect of P53 Arg72Pro, P73 G4C14-to-A4T14, and MDM2
FIGURE 4. Kaplan-Meier curves of (A) overall survival (log-rank p  0.112) and (B) progression-free survival (log-rank p 
0.181) by combined unfavorable genotypes in P53, P73, and MDM2 genes.
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T309G polymorphisms on OS in advanced NSCLC patients
treated with platinum-based chemotherapy, suggesting that these
polymorphisms may serve as promising biomarkers for individ-
ualized chemotherapy and prognosis of NSCLC patients.
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